Clareo Health | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kumquat Biosciences Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PART 1 - Histologically confirmed diagnosis of a solid tumor malignancy with any of the following oncogenic mutations: EGFR, RAS, PTPN11, or SOS1 mutations, or inactivating mutations of NF1.
PART 1 - (Osimertinib and Amivantamab arms) and Part 2 Cohort A and Cohort B: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib
Part 3 - Cohort A: Histologically confirmed diagnosis of NSCLC with exon 20 insertion EGFR mutation
Unresectable or metastatic disease
No available treatment with curative intent
Adequate organ function
Measurable disease per RECIST 1.1.
You may not be if
Prior therapy with a similar mechanism of action to KQB198
History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
